Evaluation of MERS-CoV Neutralizing Antibodies in Sera Using Live Virus Microneutralization Assay.
Identifieur interne : 000309 ( PubMed/Curation ); précédent : 000308; suivant : 000310Evaluation of MERS-CoV Neutralizing Antibodies in Sera Using Live Virus Microneutralization Assay.
Auteurs : Abdullah Algaissi [États-Unis] ; Anwar M. Hashem [Arabie saoudite]Source :
- Methods in molecular biology (Clifton, N.J.) [ 1940-6029 ] ; 2020.
Abstract
The microneutralization (MN) assay is a standard and important technique in virology, immunology, and epidemiology. It is a highly specific and sensitive assay for evaluating virus-specific neutralizing antibodies (nAbs) in human and animal sera. It provides the most precise answer to whether or not an individual or animal has antibodies that can neutralize or inhibit the infectivity of a specific virus strain. However, using live virus-based MN assay might require working under high containment facilities especially when dealing with high-risk pathogens such as the Middle East respiratory syndrome-coronavirus (MERS-CoV). In this chapter, we describe the isolation, amplification, and titration of MERS-CoV, as well as detailed MN assay to measure nAb levels in sera from different mammalian species.
DOI: 10.1007/978-1-0716-0211-9_9
PubMed: 31883091
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000309
Links to Exploration step
pubmed:31883091Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Evaluation of MERS-CoV Neutralizing Antibodies in Sera Using Live Virus Microneutralization Assay.</title>
<author><name sortKey="Algaissi, Abdullah" sort="Algaissi, Abdullah" uniqKey="Algaissi A" first="Abdullah" last="Algaissi">Abdullah Algaissi</name>
<affiliation wicri:level="1"><nlm:affiliation>Departments of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Departments of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hashem, Anwar M" sort="Hashem, Anwar M" uniqKey="Hashem A" first="Anwar M" last="Hashem">Anwar M. Hashem</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia. amhashem@kau.edu.sa.</nlm:affiliation>
<country xml:lang="fr">Arabie saoudite</country>
<wicri:regionArea>Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:31883091</idno>
<idno type="pmid">31883091</idno>
<idno type="doi">10.1007/978-1-0716-0211-9_9</idno>
<idno type="wicri:Area/PubMed/Corpus">000309</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000309</idno>
<idno type="wicri:Area/PubMed/Curation">000309</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000309</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Evaluation of MERS-CoV Neutralizing Antibodies in Sera Using Live Virus Microneutralization Assay.</title>
<author><name sortKey="Algaissi, Abdullah" sort="Algaissi, Abdullah" uniqKey="Algaissi A" first="Abdullah" last="Algaissi">Abdullah Algaissi</name>
<affiliation wicri:level="1"><nlm:affiliation>Departments of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Departments of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hashem, Anwar M" sort="Hashem, Anwar M" uniqKey="Hashem A" first="Anwar M" last="Hashem">Anwar M. Hashem</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia. amhashem@kau.edu.sa.</nlm:affiliation>
<country xml:lang="fr">Arabie saoudite</country>
<wicri:regionArea>Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Methods in molecular biology (Clifton, N.J.)</title>
<idno type="eISSN">1940-6029</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The microneutralization (MN) assay is a standard and important technique in virology, immunology, and epidemiology. It is a highly specific and sensitive assay for evaluating virus-specific neutralizing antibodies (nAbs) in human and animal sera. It provides the most precise answer to whether or not an individual or animal has antibodies that can neutralize or inhibit the infectivity of a specific virus strain. However, using live virus-based MN assay might require working under high containment facilities especially when dealing with high-risk pathogens such as the Middle East respiratory syndrome-coronavirus (MERS-CoV). In this chapter, we describe the isolation, amplification, and titration of MERS-CoV, as well as detailed MN assay to measure nAb levels in sera from different mammalian species.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">31883091</PMID>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1940-6029</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>2099</Volume>
<PubDate><Year>2020</Year>
</PubDate>
</JournalIssue>
<Title>Methods in molecular biology (Clifton, N.J.)</Title>
<ISOAbbreviation>Methods Mol. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Evaluation of MERS-CoV Neutralizing Antibodies in Sera Using Live Virus Microneutralization Assay.</ArticleTitle>
<Pagination><MedlinePgn>107-116</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/978-1-0716-0211-9_9</ELocationID>
<Abstract><AbstractText>The microneutralization (MN) assay is a standard and important technique in virology, immunology, and epidemiology. It is a highly specific and sensitive assay for evaluating virus-specific neutralizing antibodies (nAbs) in human and animal sera. It provides the most precise answer to whether or not an individual or animal has antibodies that can neutralize or inhibit the infectivity of a specific virus strain. However, using live virus-based MN assay might require working under high containment facilities especially when dealing with high-risk pathogens such as the Middle East respiratory syndrome-coronavirus (MERS-CoV). In this chapter, we describe the isolation, amplification, and titration of MERS-CoV, as well as detailed MN assay to measure nAb levels in sera from different mammalian species.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Algaissi</LastName>
<ForeName>Abdullah</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Departments of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Medical Laboratories Technology, College of Applied Medical Sciences, Jazan University, Jazan, Saudi Arabia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hashem</LastName>
<ForeName>Anwar M</ForeName>
<Initials>AM</Initials>
<AffiliationInfo><Affiliation>Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia. amhashem@kau.edu.sa.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia. amhashem@kau.edu.sa.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Methods Mol Biol</MedlineTA>
<NlmUniqueID>9214969</NlmUniqueID>
<ISSNLinking>1064-3745</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">MERS-CoV</Keyword>
<Keyword MajorTopicYN="Y">Microneutralization</Keyword>
<Keyword MajorTopicYN="Y">Neutralizing antibodies</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year>
<Month>12</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2019</Year>
<Month>12</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2019</Year>
<Month>12</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">31883091</ArticleId>
<ArticleId IdType="doi">10.1007/978-1-0716-0211-9_9</ArticleId>
<ArticleId IdType="pmc">PMC7121888</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Euro Surveill. 2014 Jun 12;19(23):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24957744</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>mBio. 2014 Feb 25;5(2):e00884-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24570370</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Euro Surveill. 2015;20(41):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26538277</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Clin Infect Dis. 2014 Nov 1;59(9):1225-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24829216</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet Infect Dis. 2015 May;15(5):559-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25863564</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Arch Virol. 2015 Sep;160(9):2293-300</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26138557</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol Methods. 2018 Jan;251:22-29</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28993122</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Sci Immunol. 2017 Aug 4;2(14):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28778905</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2012 Nov 8;367(19):1814-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Clin Infect Dis. 2016 Feb 15;62(4):477-483</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26565003</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Clin Virol. 2014 Oct;61(2):275-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25073585</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immunol Methods. 2019 Mar;466:41-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30659836</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Euro Surveill. 2013 Apr 04;18(14):20441</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23594517</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Med Virol. 2018 Feb;90(2):367-371</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28906003</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2014 Jun 26;370(26):2499-505</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24896817</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Euro Surveill. 2013 Sep 05;18(36):pii=20574</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24079378</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Sci Rep. 2017 Mar 23;7:44875</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28332568</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000309 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000309 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= MersV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:31883091 |texte= Evaluation of MERS-CoV Neutralizing Antibodies in Sera Using Live Virus Microneutralization Assay. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:31883091" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a MersV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |